SCHEMBL3011008

SCHEMBL3011008

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.36
PROKR1 Q8TCW9 3/20 0.35
FPR2 P25090 2/20 0.35
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR7 P34969 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
NAAA Q02083 4/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
GPR6 P46095 1/20 0.33
MAPK1 P28482 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016743 0.94 CTSS (0.36) CTSSKMT2ANAAACNR1CNR2
SCHEMBL3011944 0.93 SOS1 (0.37) CTSSKMT2ASMN1; SMN2HTR7NAAA
SCHEMBL3009006 0.92 SMN1; SMN2 (0.37) CTSSSMN1; SMN2HRH3NAAACNR1
SCHEMBL3012974 0.91 MAPT (0.38) CTSSKMT2ASMN1; SMN2NAAAMAPK1
SCHEMBL3008760 0.91 CTSS (0.45) CTSSPROKR1FPR2SMN1; SMN2HRH3
SCHEMBL3005426 0.91 CTSS (0.39) CTSSPROKR1FPR2SMN1; SMN2HRH3
SCHEMBL3018837 0.90 NAAA (0.35) CTSSKMT2ASMN1; SMN2HRH3NAAA
SCHEMBL3019125 0.90 KMT2A (0.36) CTSSKMT2ASMN1; SMN2HRH3NAAA
SCHEMBL3007781 0.89 PROKR1 (0.38) CTSSPROKR1FPR2SMN1; SMN2HRH3
SCHEMBL3011191 0.89 NAAA (0.36) KMT2ASMN1; SMN2HRH3NAAACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885PROKR1 2080/4885FPR2 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.